All News
EULAR 2017 – Day 2 Highlights
The heat was on at EULAR 2017 for busy presenters and attendees navigating the 104F degree temperatures at the indoor/outdoor IFEMA Convention center in Madrid.
Day 2 (Thursday) were big days for gout, drug safety, psoriatic arthritis and spondyloarthritis.
Read ArticleDigital Epidemiology
Today I came across two interesting sessions given by Gossec Laure from France and William Dixon from the United Kingdom. They talked about digital epidemiology in this changing world, as there are approximately 15 billion connected devices and more than 80,000 medical apps.
Read ArticleNew insights into the impact of pegloticase in chronic refractory gout
Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions. It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions.
Read Articlelxekizumab Performance in TNF Nonresponders Phase 3 Trial
Lxekizumab performs well in TNF nonresponders phase 3 trial.
With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies, the question of efficacy and safety in different clinical scenarios arises. The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:Arial;
color:black;}
Treat-to-Target in Spondyloarthropathies
Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.
Read Article
EULAR 2017 – Day 1 Highlights
The Annual EULAR Congress kicked off this afternoon in Madrid with a number of new sessions devoted to important topics.
Read Article
Wearable Technologies Coming of Age
The first day of EULAR 2017 highlighted a symposium focus on the advances in wearable technologies. Several lectures updated attendees with the state of wearables in society and their implications on public health, fitness, weight loss and clinical trials.
Read ArticleRheumatic IRAEs Gaining Speed
Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.
Read Article
Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"
The current Lancet edition for 10 June 2017 is a rheumatology rich collection.
Read Article
The RheumNow Week in Review – 9 June 2017
Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:
Read Article
Biosimilar Reports – May 2017
Biosimilars continue to command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. Biosimilar Reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists.
Read Article
The RheumNow Week in Review – 2 June 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review - 26 May 2017
Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:
Read Article
The RheumNow Week in Review – 17 May 2017
Dr. Jack Cush reviews highlights and updates from the past week on RheumNow.com:
Read Article
Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis
Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.
Read Article
No Arthroscopy Needed for Degenerative Knees and Meniscal Tears
The British Medical Journal has published a clinical practice guideline for the use of arthroscopic surgery for degenerative knee arthritis and meniscal tears, suggesting that many patients will not benefit from such surgery.
Read Article
The RheumNow Week in Review – 12 May 2017
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Read Article
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
The RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read Article
US Drug Spending Will Rise Steadily Thru 2021
Reuters has reported that U.S.spending on prescription drugs in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.
Read Article
